GLS - GLS STOCK NEWS

Gelesis (NYSE: GLS), creator of the FDA-cleared weight management product Plenity, will participate in the 25th Annual ICR Conference in Orlando, Florida, on January 9, 2023. The company will deliver a presentation at 1:30 p.m. ET, which can be accessed via the 'Events & Presentations' section on Gelesis' Investor Relations website. This conference presents an opportunity for Gelesis to engage with investors and discuss the progress and future of their innovative weight management solutions.

Gelesis Holdings Inc. (NYSE: GLS) has received a notification from the New York Stock Exchange indicating it is not in compliance with listing standards due to a market capitalization and stockholders' equity below $50 million. The company has a Cure Period of 18 months to formulate a compliance plan, which must be submitted within 45 days. Gelesis intends to develop this plan and will be monitored quarterly by the NYSE. During this period, its stock will trade with a '.BC' designation to indicate non-compliance.

Gelesis Holdings reported a strong Q3 2022 with a 114% increase in product revenue, totaling $6.4 million, driven by 23,500 new members and 92,000 units sold. Gross profit surged to $2.8 million, improving gross margin to 44%. The company plans to submit Plenity for OTC status, potentially enhancing market reach and reducing customer acquisition costs. Despite a net loss of $(14.1) million, the financial outlook remains positive, with expected revenue between $27 million and $30 million for FY 2022.

Gelesis Holdings (NYSE: GLS) announced it will report its third-quarter financial results for the period ending September 30, 2022, on November 14, 2022, before the market opens. A live conference call will be held at 8:30 a.m. ET on the same day to discuss the results. Gelesis is known for its weight management product, Plenity®, which is designed to aid in weight management and is inspired by natural ingredients.

Gelesis Holdings Inc. (NYSE: GLS) received a notification from the New York Stock Exchange regarding non-compliance with listing standards due to its stock closing below $1.00 for 30 consecutive trading days. The Company will remain listed as it works to regain compliance within a six-month cure period. Gelesis aims to address this issue by exploring all available options to ensure the stock price meets the required standards. A timely response to the NYSE has been assured to confirm the intent to return to compliance.

Gelesis Holdings Inc. (NYSE: GLS) announced new findings at Obesity Week in San Diego, revealing that an oral superabsorbent hydrogel (Gel-B) promotes the growth of Akkermansia muciniphila, beneficial for gut health and weight management. The study compared Gel-B's effects against prebiotics like inulin and psyllium, showing significant growth of A. muciniphila within two weeks post-treatment. This research enhances understanding of how Gel-B may influence microbiome health, leading to further studies on human applications.

Gelesis Holdings (NYSE: GLS) reported findings from the LIGHT-UP study presenting Waist to Height Ratio as a strong predictor of weight loss response to GS200 treatment in individuals with prediabetes or type 2 diabetes.

Notably, 6 out of 10 participants achieved an average weight loss of 11% (approximately 23 pounds) and a waist reduction of 5.6 inches over 25 weeks. Dr. Frank Greenway will present these findings at Obesity Week in San Diego on November 2. The study indicates a high correlation between insulin resistance metrics and weight loss outcomes, emphasizing GS200's potential in weight management.

Gelesis Holdings Inc. (NYSE: GLS) announced participation in the Jefferies Virtual Fitness & Wellness Summit on September 12, 2022. The event will feature a fireside chat at 9:30 a.m. ET with key executives, including Founder Yishai Zohar and CFO Elliot Maltz. The live webcast will be accessible via the Gelesis Investor Relations website and will also be archived for later viewing.

Gelesis is known for its weight management product, Plenity, which is designed to aid adults with excess weight or obesity.

Gelesis Holdings (NYSE: GLS) presented findings from the LIGHT-UP study at the International Congress of Endocrinology in Singapore. The 25-week trial, involving 254 participants with prediabetes or type 2 diabetes, met its primary endpoints, demonstrating GS200's effectiveness in weight management. One-third of participants achieved a minimum 10% weight loss, averaging 13% (~30 pounds). Additionally, GS200 showed significant reductions in mealtime insulin release, highlighting its potential beyond weight loss. The favorable safety profile suggests promising market potential for GS200.